Evonik has entered a strategic partnership with InVitria to supply animal component-free (ACF) recombinant human serum albumin to the global biopharmaceutical industry. The collaboration brings together Evonik’s global reach and expertise in cell culture ingredients with InVitria’s advanced recombinant production technology. It also enables more customers to access high-quality, animal-free ingredients that enhance process efficiency and product stability across cell culture and biologics formulations.
“By combining our expertise in cell culture and parenteral drug product solutions with InVitria’s innovative recombinant technologies, we are well positioned to support the development of highly innovative biopharmaceuticals. This collaboration is the starting point for Evonik’s future growth in recombinant proteins,” said Guido Skudlarek, head of the Health Care business line.
Evonik will distribute InVitria’s blood-free recombinant human serum albumin (rHSA) portfolio to its biopharma customers. InVitria’s rHSA is a highly pure recombinant version of albumin - a key protein used to stabilize, protect, and transport molecules in drug development. InVitria’s rHSA is expressed in a non-mammalian host, eliminating reliance on animal- or human-derived serum proteins. This avoids the risks of contamination, supply limitations, and batch variability. The result is a safer, more consistent ingredient that supports improved process efficiency and product stability across a wide range of biopharmaceutical applications such as cell culture, gene therapy, vaccine development or regenerative medicine.
"This collaboration strengthens our shared commitment to providing reliable, animal-origin-free protein solutions that enhance process efficiency, ensure product quality, and accelerate innovation across the life sciences,” said Scott Deeter, CEO of InVitria.
The market for recombinant human serum albumin is projected to grow nearly 10 percent (CAGR) from 2025 to 2033. This growth is fueled by a demand for safe animal-free protein alternatives in the biopharmaceutical industry.